帕米膦酸二钠联合化疗治疗骨转移癌临床观察

Therapeutic effect of pamidronate combined with chemotherapy on bone metastases cancer

目的观察帕米膦酸二钠联合化疗对骨转移癌的疗效及不良反应。方法42例恶性肿瘤骨转移患者随机分为单用帕米膦酸二钠组20例（单用组）及帕米膦酸二钠联合化疗组22例（联合组），联合组患者采用帕米膦酸二钠联合如下方案：非小细胞肺癌用NP方案，小细胞肺癌用EP方案，乳腺癌用CAF方案，前列腺癌用FAM方案。结果单用组镇痛有效率为65．0％，联合组为90．9％，两组差异有统计学意义（Χ^2=4．17，P〈0．05），两组KPS评分改善情况及活动能力改善情况差异无统计学意义（P〉0．05）。结论帕米膦酸二钠联合化疗是治疗晚期恶性肿瘤骨转移的有效方案，不能耐受化疗的晚期肿瘤患者单用帕米膦酸二钠治疗，也可获得令人满意效果。

Objective To study the curative effect and adverse drug reactions of pamidronate combination with chemotherapy in treatment of bone metastatic cancer. Methods 42 cases of cancer patients with bone metastasis are divided into two groups,20 patients in one group are treated with pamidronate only（ pamidronate group） ,22 patients in the other group are treated with pamidronate combination with chemotherapy（combination group）. Combined chemotherapy regiments in combination group are：NP regiment in non-small cell lung cancer, CAF regiment in mammary carcinoma,FAM regiment in prostate cancer. Results The effective rate of analgesia in pamidronate group is 65% ,combination group is 90.9%. There is statistically significant difference between two groups （Χ^2 = 4. 17, P 〈 0. 05）. There is no statistically significant difference in improvement of Kap grade and ability in activity between two groups （P 〉 0. 05）. Conclusion Pamidronate combination with chemotherapy is an effective curative method for bone metastasis of advanced malignant tumor. Pamidronate only is a satisfactory curative method for advanced malignant tumor patients that can not endure chemotherapy.